Your browser doesn't support javascript.
loading
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).
Stahl, Maximilian; Bewersdorf, Jan Philipp; Xie, Zhuoer; Porta, Matteo Giovanni Della; Komrokji, Rami; Xu, Mina L; Abdel-Wahab, Omar; Taylor, Justin; Steensma, David P; Starczynowski, Daniel T; Sekeres, Mikkael A; Sanz, Guillermo; Sallman, David A; Roboz, Gail J; Platzbecker, Uwe; Patnaik, Mrinal M; Padron, Eric; Odenike, Olatoyosi; Nimer, Stephen D; Nazha, Aziz; Majeti, Ravi; Loghavi, Sanam; Little, Richard F; List, Alan F; Kim, Tae Kon; Hourigan, Christopher S; Hasserjian, Robert P; Halene, Stephanie; Griffiths, Elizabeth A; Gore, Steven D; Greenberg, Peter; Figueroa, Maria E; Fenaux, Pierre; Efficace, Fabio; DeZern, Amy E; Daver, Naval G; Churpek, Jane E; Carraway, Hetty E; Buckstein, Rena; Brunner, Andrew M; Boultwood, Jacqueline; Borate, Uma; Bejar, Rafael; Bennett, John M; Wei, Andrew H; Santini, Valeria; Savona, Michael R; Zeidan, Amer M.
Afiliação
  • Stahl M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
  • Bewersdorf JP; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Xie Z; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Porta MGD; IRCCS Humanitas Clinical and Research Center & Humanitas University, Department of Biomedical Sciences, via Manzoni 56, 20089, Rozzano, Milan, Italy.
  • Komrokji R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Xu ML; Departments of Pathology & Laboratory Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
  • Abdel-Wahab O; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Taylor J; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Steensma DP; David Steensma LLC, Cambridge, Massachusetts 02139, USA.
  • Starczynowski DT; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
  • Sekeres MA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Sanz G; Health Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain.
  • Sallman DA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Roboz GJ; Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY, USA.
  • Platzbecker U; Leipzig University Hospital, Leipzig, Germany.
  • Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
  • Padron E; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Odenike O; Leukemia Program, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
  • Nimer SD; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Nazha A; Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
  • Majeti R; Division of Hematology, Department of Medicine, Cancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Palo Alto, CA, USA.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Little RF; National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD, USA.
  • List AF; Precision BioSciences, Inc., Durham, NC, USA.
  • Kim TK; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Hourigan CS; Laboratory of Myeloid Malignancies, Hematology Branch, National Heart, Lung, and Blood Institute, and Myeloid Malignancies Program, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Hasserjian RP; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
  • Halene S; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA.
  • Griffiths EA; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Gore SD; National Cancer Institute, Cancer Therapy Evaluation Program, Rockville, MD, USA.
  • Greenberg P; Division of Hematology, Department of Medicine, Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Figueroa ME; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
  • Fenaux P; Hôpital Saint Louis, Assistance Publique Hôpitaux de Paris and Paris Cité University, Paris, France.
  • Efficace F; Italian Group for Adult Hematologic Diseases (GIMEMA), Health Outcomes Research Unit, Rome, Italy.
  • DeZern AE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA.
  • Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Churpek JE; Department of Hematology, Oncology, and Palliative Care, Carbone Cancer Center, The University of Wisconsin-Madison, Madison, WI, USA.
  • Carraway HE; Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Buckstein R; Department of Medical Oncology/ Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
  • Brunner AM; Leukemia Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Boultwood J; Blood Cancer UK Molecular Haematology Unit, Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Borate U; Ohio State University Comprehensive Cancer Center/ James Cancer Hospital, Ohio State University, Columbus, OH, USA.
  • Bejar R; Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, CA, USA.
  • Bennett JM; University of Rochester Medical Center, Department of Pathology and Laboratory Medical Center, Rochester, NY, USA.
  • Wei AH; Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research and University of Melbourne, Victoria, Australia.
  • Santini V; MDS Unit, Hematology, AOUC, University of Florence, Italy.
  • Savona MR; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu.
Blood Rev ; 62: 101128, 2023 11.
Article em En | MEDLINE | ID: mdl-37704469
The guidelines for classification, prognostication, and response assessment of myelodysplastic syndromes/neoplasms (MDS) have all recently been updated. In this report on behalf of the International Consortium for MDS (icMDS) we summarize these developments. We first critically examine the updated World Health Organization (WHO) classification and the International Consensus Classification (ICC) of MDS. We then compare traditional and molecularly based risk MDS risk assessment tools. Lastly, we discuss limitations of criteria in measuring therapeutic benefit and highlight how the International Working Group (IWG) 2018 and 2023 response criteria addressed these deficiencies and are endorsed by the icMDS. We also address the importance of patient centered care by discussing the value of quality-of-life assessment. We hope that the reader of this review will have a better understanding of how to classify MDS, predict clinical outcomes and evaluate therapeutic outcomes.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Neoplasias Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Neoplasias Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article